<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777357</url>
  </required_header>
  <id_info>
    <org_study_id>3112-301-001</org_study_id>
    <secondary_id>2020-004758-32</secondary_id>
    <nct_id>NCT04777357</nct_id>
  </id_info>
  <brief_title>A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder</brief_title>
  <official_title>A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Participants (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult&#xD;
      population and 1.8% of the pediatric population in the United States. The treatment of the&#xD;
      depressive episodes of bipolar disorder in the pediatric population has not been as widely&#xD;
      studied as the treatment of depressive episodes in bipolar disorder in adults, therefore&#xD;
      pharmacotherapeutic options are limited. Given the change in disease state and safety&#xD;
      demonstrated in adults with depressive episodes associated with bipolar I disorder, the&#xD;
      purpose of this study is to evaluate the change in disease state and safety of cariprazine in&#xD;
      the treatment of depressive episodes associated with bipolar I disorder in the pediatric&#xD;
      population.&#xD;
&#xD;
      Cariprazine is an approved drug for the treatment of depressive episodes in adult&#xD;
      participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called&#xD;
      treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo.&#xD;
      Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in&#xD;
      approximately 60 sites worldwide.&#xD;
&#xD;
      Participants receiving the study drug will receive Dose A or B of Cariprazine based on age&#xD;
      and weight. At Week 3, participants with insufficient response will have their dose increased&#xD;
      to Dose B or Dose C, while participants with sufficient response will continue receiving the&#xD;
      Dose A or B for the remainder of the treatment period. The treatment period will be followed&#xD;
      by a safety follow-up (SFU) period for 4 weeks.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular weekly visits during the study at a&#xD;
      hospital or clinic. The effect of the treatment will be checked by medical assessments, blood&#xD;
      tests, checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">January 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Baseline (Week 0) to Week 10</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment. The investigator assesses the relationship of each event to the use of the study. A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/ treatment emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal Change from Baseline in Vital Signs</measure>
    <time_frame>Baseline (Week 0) to Week 10</time_frame>
    <description>Change in vital signs like systolic and diastolic blood pressure will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Incidence of Abnormal Clinical Laboratory Test Results</measure>
    <time_frame>Baseline (Week 0) to Week 6</time_frame>
    <description>Number of participants with incidence of abnormal clinical laboratory test results like hematology will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (ECG)</measure>
    <time_frame>Baseline (Week 0) to Week 6</time_frame>
    <description>12 -lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Children's Depression Rating Scale - Revised (CDRS-S) Total Score</measure>
    <time_frame>Baseline (Week 0) to Week 10</time_frame>
    <description>The CDRS-R is a 17 item scale with items ranging from 1 to 5 or 1 to 7 used to assess depression and change in depression symptoms in children and adolescents. Scores greater than or equal to 40 are indicative of depression. Scores less than or equal to 28 are often used to define minimal or no symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Depression</condition>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo over a 6 week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive flexible dose Cariprazine over a 6 week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Cariprazine</arm_group_label>
    <other_name>Vraylar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition&#xD;
             (DSM-5) primary diagnosis of bipolar I disorder as confirmed by Kiddie Schedule for&#xD;
             Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime&#xD;
             Version (K-SADS-PL).&#xD;
&#xD;
          -  Current depressive episode is more than 4 weeks and less than 12 months in duration.&#xD;
&#xD;
          -  Participant has a lifetime history of at least one manic episode.&#xD;
&#xD;
          -  Children's Depression Rating Scale - Revised (CDRS-R) score &gt; = 45 at Visit 1 and&#xD;
             Visit 2.&#xD;
&#xD;
          -  Young-Mania Rating Scale (YMRS) score &lt; = 12 with YMRS Item 1 (elevated mood) score &lt;&#xD;
             = 2 at Visit 1 and Visit 2.&#xD;
&#xD;
          -  Clinical Global Impression-Severity (CGI-S) scale score of &gt; = 4 (moderately ill) at&#xD;
             Visit 1 and Visit 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with DSM-5 diagnosis of schizophrenia, schizoaffective disorder,&#xD;
             schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another&#xD;
             medical condition, PTSD, antisocial personality disorder, or borderline personality&#xD;
             disorder.&#xD;
&#xD;
          -  Participant has a history of meeting DSM-5 diagnosis for any substance-related&#xD;
             disorder within the 3 months before Screening Visit 1.&#xD;
&#xD;
          -  History of serotonin syndrome or neuroleptic malignant syndrome.&#xD;
&#xD;
          -  Four or more episodes of a mood disturbance within the 12 months before Visit 1.&#xD;
&#xD;
          -  DSM-5 diagnosis of intellectual disability (IQ &lt; 70), autism spectrum disorders, or&#xD;
             documented history of chromosomal disorder with developmental impairment.&#xD;
&#xD;
          -  History of seizures, with the exception of febrile seizures.&#xD;
&#xD;
          -  Significant head trauma, history of tumor of the CNS, or any other condition that&#xD;
             predisposes to seizures.&#xD;
&#xD;
          -  Participant requires concomitant treatment with moderate or strong CYP3A4 inhibitors&#xD;
             or with any CYP3A4 inducers.&#xD;
&#xD;
          -  Participant requires concomitant treatment with any prohibited medication, supplement,&#xD;
             or herbal product, including any psychotropic drug or any drug with psychotropic&#xD;
             activity or with a potentially psychotropic component.&#xD;
&#xD;
          -  Use of a depot antipsychotic within 2 cycles of their respective dosing interval prior&#xD;
             to Screening Visit 1.&#xD;
&#xD;
          -  Treatment with clozapine in a dose of &gt; 50 mg/d in the past 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pillar Clinical Research /ID# 226504</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center /ID# 227073</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Care Access Research /ID# 226316</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group /ID# 226223</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230-6632</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Alliance Research /ID# 226522</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prospective Research Innovations Inc /ID# 240774</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Department of Psychiatry /ID# 226463</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Management Group /ID# 227075</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786-3676</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute of Miami /ID# 228222</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030-4613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Research Ph I-IV /ID# 240778</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166-7225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Services, Llc /Id# 229792</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125-5114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Center, Inc. /ID# 240775</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research /ID# 226480</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 228695</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Behavioral Research, LLC /ID# 226486</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 226371</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baber Research Group /ID# 232279</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563-6502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Kennedy Krieger Institute /ID# 226509</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroCognitive and Behavioral Institute, Inc /ID# 227077</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>07856-1315</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UB Department of Psychiatry /ID# 226373</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research /ID# 228548</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618-1609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Berma Research Group /ID# 229782</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501-1603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Therapeutics of Avon Lake /ID# 226349</name>
      <address>
        <city>Avon Lake</city>
        <state>Ohio</state>
        <zip>44012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 226465</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CincyScience /ID# 226318</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 227072</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research /ID# 226384</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group /ID# 240777</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116-1423</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin /ID# 227076</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759-5290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials /ID# 227156</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest Biomed Research Center LLC /ID# 226340</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates /ID# 240776</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090-2641</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AIM Trials /ID# 226367</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of The Woodlands /ID# 226290</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asociatia Comunitatea Oamenilor /ID# 226514</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200157</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Neuropsihiatrie Infantila Timisoara /Id# 226347</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300329</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul de Psihiatrie Socola Iasi /ID# 226200</name>
      <address>
        <city>Iasi</city>
        <zip>700282</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychotherapeutics Center Podderzhka /ID# 226348</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Skiy Kray</state>
        <zip>355029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica of Glazunova /ID# 229416</name>
      <address>
        <city>Krasnodar</city>
        <zip>350051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Centre of Personalized Medicine /ID# 226380</name>
      <address>
        <city>Moscow</city>
        <zip>105082</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Clinical Psychiatric Hospital /ID# 226381</name>
      <address>
        <city>Moscow</city>
        <zip>127083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatry Hospital #1 of Nizhniy Novgorod /ID# 226226</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Psychiatric Hospital #1 /ID# 226462</name>
      <address>
        <city>Orenburg</city>
        <zip>460006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>I. I. Skvortsov-Stepanov Psychiatric Hospital #3 /ID# 226346</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medgard Clinic /ID# 228598</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saratov City Clinical Hospital #2 n.a. V. I. Razumovsky /ID# 226222</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatric hospital #1 /ID# 226516</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev /ID# 226515</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Kragujevac /ID# 229138</name>
      <address>
        <city>Kragujevac</city>
        <state>Sumadijski Okrug</state>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center Vojvodina /ID# 226521</name>
      <address>
        <city>Novi Sad</city>
        <state>Vojvodina</state>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth /ID# 226513</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Mental Health /ID# 227157</name>
      <address>
        <city>Belgrade</city>
        <zip>11108</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for mental health protection, Clinical Centre Nis /ID# 229137</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SIC Institute of Health Care for Children and Adolescents of the NAMS of Ukraine /ID# 226506</name>
      <address>
        <city>Kharkiv</city>
        <zip>61153</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNE of LOR Lviv Regional Clinical Psychiatric Hospital /ID# 226461</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MNCE Odesa Regional Medical Center for Mental Health /ID# 226231</name>
      <address>
        <city>Odesa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MNCE Odesa Regional Medical Center for Mental Health /ID# 226382</name>
      <address>
        <city>Odesa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>RGH-188</keyword>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Vraylar</keyword>
  <keyword>Cariprazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cariprazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

